PHG vs DXCM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PHG · Royal Philips$28.61 ▼ 2.19%
DXCM · DexCom$79.32 ▼ 1.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PHG +8.7%
- DXCM +27.5%
Head to head
| Metric | PHG | DXCM |
|---|---|---|
| Price | $28.61 | $79.32 |
| Change today | ▼ 2.19% | ▼ 1.08% |
| Market cap | $27.97B | $29.58B |
| Return, 3 months | +4.0% | -12.9% |
| Return, year to date | +9.8% | +19.5% |
| Return, 1 year | +9.1% | +31.7% |
| P/E (TTM) | 26.3 | 31.2 |
| P/B | 2.2 | 11.7 |
| P/E percentile vs own 5y | 82nd | 6th |
| Dividend yield | 3.44% | – |
| Revenue growth (YoY, latest qtr) | +2.1% | +11.2% |
| Net profit growth (YoY) | -85.0% | -3.1% |
| Gross margin | 46.4% | 63.4% |
| Operating margin | 8.9% | 24.0% |
| Net margin | 5.4% | 19.4% |
| Return on equity | 8.6% | 37.7% |
| Analyst target vs. price | – | +25.1% |
| Analyst buy share | 0% | 93% |
| RSI (14) | 51 | 43 |
| 30-day volatility | 33.7% | 45.7% |
| Max drawdown, 1 year | -24.8% | -22.6% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DXCM is the largest of the group by market value.
- DXCM has returned the most over the past year.
- PHG carries the lowest trailing P/E.
- DXCM is growing revenue fastest.
- DXCM keeps the most profit per dollar of sales.
- PHG has been the calmest stock over the last 30 days.